The risk of developing Parkinson’s disease (PD) has been reported to be decreased with antihypertensive medications, particularly angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-II receptor-blockers (ARB) [1, 2], as well as calcium channel blockers (CCB) [3–5]. Here, ACE is linked to Parkinson disease.